Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
EW

EW - Edwards Lifesciences Corp Stock Price, Fair Value and News

87.65USD-0.12 (-0.14%)Market Closed

Market Summary

EW
USD87.65-0.12
Market Closed
-0.14%

EW Alerts

  • 1 major insider buys and 3 major insider sales recently.

EW Stock Price

View Fullscreen

EW RSI Chart

EW Valuation

Market Cap

52.8B

Price/Earnings (Trailing)

37.38

Price/Sales (Trailing)

8.6

EV/EBITDA

29.28

Price/Free Cashflow

194.61

EW Price/Sales (Trailing)

EW Profitability

EBT Margin

26.19%

Return on Equity

19.85%

Return on Assets

14.51%

Free Cashflow Yield

0.51%

EW Fundamentals

EW Revenue

Revenue (TTM)

6.1B

Rev. Growth (Yr)

9.5%

Rev. Growth (Qtr)

4.18%

EW Earnings

Earnings (TTM)

1.4B

Earnings Growth (Yr)

3.35%

Earnings Growth (Qtr)

-5.07%

Breaking Down EW Revenue

Last 7 days

0.0%

Last 30 days

1.4%

Last 90 days

-5.1%

Trailing 12 Months

-3.2%

How does EW drawdown profile look like?

EW Financial Health

Current Ratio

3.75

Debt/Equity

0.08

Debt/Cashflow

0.88

EW Investor Care

Buy Backs (1Y)

0.60%

Diluted EPS (TTM)

2.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20246.1B000
20235.5B5.7B5.8B6.0B
20225.4B5.4B5.4B5.4B
20214.5B4.9B5.1B5.2B
20204.5B4.3B4.4B4.4B
20193.8B4.0B4.2B4.3B
20183.4B3.5B3.6B3.7B
20173.1B3.2B3.3B3.4B
20162.6B2.7B2.9B3.0B
20152.4B2.4B2.4B2.5B
20142.1B2.1B2.2B2.3B
20131.9B2.0B2.0B2.0B
20121.7B1.8B1.8B1.9B
20111.5B1.6B1.6B1.7B
20101.3B1.4B1.4B1.4B
20091.3B1.3B1.3B1.3B
20080001.2B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Edwards Lifesciences Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
bobo donald e jr
sold
-437,696
87.5393
-5,000
cvp,strategy/corp development
Jun 12, 2024
bobo donald e jr
acquired
226,384
45.2767
5,000
cvp,strategy/corp development
May 30, 2024
zovighian bernard j
sold
-755,539
87.68
-8,617
ceo
May 21, 2024
ullem scott b.
sold
-508,803
90.4539
-5,625
cvp, chief financial officer
May 21, 2024
ullem scott b.
acquired
254,681
45.2767
5,625
cvp, chief financial officer
May 11, 2024
lemercier jean-luc m
sold (taxes)
-3,642
86.72
-42.00
cvp, emeacla and japac
May 11, 2024
bobo donald e jr
sold (taxes)
-70,590
86.72
-814
cvp,strategy/corp development
May 11, 2024
wood larry l
sold (taxes)
-85,419
86.72
-985
global president tavr & surg
May 11, 2024
lippis daniel j.
sold (taxes)
-65,386
86.72
-754
cvp, japac
May 11, 2024
szyman catherine m.
sold (taxes)
-71,717
86.72
-827
cvp, critical care

1–10 of 50

Which funds bought or sold EW recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-56.48
-59,018
55,205
-%
Jun 07, 2024
Railway Pension Investments Ltd
reduced
-10.56
17,484,000
162,030,000
1.58%
Jun 05, 2024
Objective Capital Management, LLC
added
0.1
198,593
979,012
0.66%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-13.85
14,847,000
188,377,000
0.35%
May 31, 2024
Maxwell Wealth Strategies Inc.
added
481
1,556,330
1,829,080
0.93%
May 30, 2024
CAMBRIDGE TRUST CO
unchanged
-
27,806
137,606
-%
May 29, 2024
Soltis Investment Advisors LLC
added
0.11
135,120
666,008
0.07%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
94.73
5,769,000
9,773,000
0.09%
May 24, 2024
PGGM Investments
new
-
208,000
208,000
-%
May 24, 2024
Cetera Investment Advisers
added
205
10,291,500
13,936,400
0.03%

1–10 of 48

Are Funds Buying or Selling EW?

Are funds buying EW calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EW
No. of Funds

Unveiling Edwards Lifesciences Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.63%
52,362,913
SC 13G/A
Jan 25, 2024
blackrock inc.
8.6%
52,171,889
SC 13G/A
Feb 09, 2023
vanguard group inc
8.34%
51,559,391
SC 13G/A
Feb 07, 2023
blackrock inc.
8.6%
53,060,508
SC 13G/A
Feb 09, 2022
vanguard group inc
7.86%
49,076,649
SC 13G/A
Feb 03, 2022
blackrock inc.
9.1%
57,040,983
SC 13G/A
Feb 10, 2021
vanguard group inc
7.76%
48,347,685
SC 13G/A
Jan 29, 2021
blackrock inc.
9.4%
58,596,560
SC 13G/A
Feb 12, 2020
vanguard group inc
7.79%
16,261,702
SC 13G/A
Feb 05, 2020
blackrock inc.
8.7%
18,200,799
SC 13G/A

Recent SEC filings of Edwards Lifesciences Corp

View All Filings
Date Filed Form Type Document
Jun 13, 2024
4/A
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
8-K
Current Report
May 30, 2024
144
Notice of Insider Sale Intent
May 30, 2024
4
Insider Trading
May 30, 2024
SD
SD
May 21, 2024
144
Notice of Insider Sale Intent
May 21, 2024
4
Insider Trading
May 13, 2024
4
Insider Trading

Peers (Alternatives to Edwards Lifesciences Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.2
5.22
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.88
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.86
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.03
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.53
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
248.7M
324.0M
0.65% -42.87%
-1.29
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.49
5.77% 8.23%

Edwards Lifesciences Corp News

Latest updates
MarketWatch9 hours ago
Yahoo Finance Australia10 Jun 202403:40 pm

Edwards Lifesciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.2%1,5981,5341,4811,5301,4601,3481,3191,3741,3411,3301,3101,3761,2171,1921,1419251,1291,1741,0941,087993
Gross Profit3.0%1,2131,1771,1311,1871,1301,0901,0651,1051,0421,0209991,042923895860687864888802783761
  S&GA Expenses2.0%490480440469436411377409370424364375331339307275308347306309280
  R&D Expenses5.6%285270270270261232234251229233238225207196196182187194196192171
EBITDA Margin-1.0%0.29*0.29*0.31*0.31*0.34*0.36*0.34*0.34*0.36*0.35*0.36*0.36*---------
Interest Expenses208.6%17.00-15.2015.009.009.0011.007.001.001.0020.00-0.80-1.000.009.001.002.005.0014.003.002.002.00
Income Taxes12.3%58.0052.0056.0033.0058.0061.0064.0058.0063.0041.0051.0056.0051.0047.0039.00-46.3054.0035.0027.0029.0028.00
Earnings Before Taxes-2.9%409422439339399459407465436376391546389356364-168365316302271278
EBT Margin-1.6%0.26*0.27*0.28*0.28*0.31*0.33*0.31*0.31*0.33*0.33*0.33*0.34*---------
Net Income-5.1%352371385306341398344406374335340490338310325-121311280275242250
Net Income Margin-1.5%0.23*0.23*0.25*0.25*0.27*0.28*0.27*0.27*0.29*0.29*0.29*0.30*---------
Free Cashflow-346.0%-11848.00356-14.30253214250289221284471457---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.0%9,7369,3639,3719,0048,6518,2938,6388,4258,4208,5038,1607,6627,2147,2376,8016,4246,0766,4885,9665,5745,469
  Current Assets3.3%4,1714,0364,0683,6473,2573,0963,5143,2633,2413,1813,5163,3233,0693,0912,9802,6902,5082,9842,7402,3552,369
    Cash Equivalents7.0%1,2251,1441,4101,0438767731,2521,2031,0358631,5201,3261,1911,2001,0309096681,1841,187727709
  Inventory3.3%1,2071,1681,032980914876758740731727738760768802773735662641611625631
  Net PPE1.1%1,7681,7491,6811,6621,6461,6331,5661,5601,5521,5471,4651,4461,4181,3951,2761,1961,1011,060974931892
  Goodwill-0.1%1,2531,2541,2971,3001,3081,1641,1591,1641,1661,1681,1701,1721,1711,1731,1701,1681,1661,1681,1571,1741,103
Liabilities-3.6%2,5502,6442,6442,5582,5892,4862,4202,4822,5752,6672,619--2,663-------
  Current Liabilities-7.1%1,1111,1951,2391,1571,0821,0229189699501,032967886799894846873747902776697647
  Long Term Debt0.0%597597597597597596596596596596596595595595595595595594594594594
    LT Debt, Non Current0.0%597597597597597596596596596596596595595595595595595594594594594
Shareholder's Equity7.0%7,1186,6506,6586,4476,0625,8076,2185,9445,8455,8365,5415,1334,6584,5744,2103,8393,9014,1483,8153,5003,448
  Retained Earnings3.9%9,3448,9928,6238,2387,9317,5907,1926,8486,4426,0685,7335,3934,9034,5654,2563,9304,0523,7423,4613,1872,944
  Additional Paid-In Capital4.6%2,3802,2742,2112,1462,0491,9691,9151,8531,7691,7001,6431,5791,4971,4381,3821,3241,6761,6231,5701,5121,449
Accumulated Depreciation-100.0%-857---750---655---599---512---
Shares Outstanding0.2%602601607608608608620622622623624623---------
Minority Interest-1.3%69.0069.0070.0071.0084.00----------------
Float----56,850---58,454---64,028---42,641---34,109-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-139.2%-53.5013741234.003142833103322933745325263014002162312074034373412.00
  Share Based Compensation46.2%45.0031.0033.0037.0039.0028.0030.0036.0032.0024.0027.0030.0028.0021.0023.0025.0024.0018.0020.0022.0021.00
Cashflow From Investing347.5%63.0014.0089.0070.001.0095.00-201130230-965-377-329-49.70-259-126-10.20-134-445-12.70-88.30-49.50
Cashflow From Financing114.9%62.00-413-14352.00-206-838-69.90-308-368-62.0039.00-59.00-27441.0034.0024.00-58637.0034.00-23144.00
  Buy Backs-100.0%0.004481748.0024986610035540697.002.001123030.001.009.00615-1.002566.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EW Income Statement

2024-03-31
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net sales$ 1,598.2$ 1,459.6
Cost of sales385.6329.5
Gross profit1,212.61,130.1
Selling, general, and administrative expenses489.7436.3
Research and development expenses285.2261.2
Intellectual property agreement and certain litigation expenses (Note 3)8.943.5
Change in fair value of contingent consideration liabilities (Note 7)0.00.7
Separation costs (Note 4)41.30.0
Operating income, net387.5388.4
Interest income, net(16.5)(8.6)
Other income, net(5.4)(1.6)
Income before provision for income taxes409.4398.6
Provision for income taxes58.458.1
Net income351.0340.5
Net loss attributable to noncontrolling interest(0.9)0.0
Net income attributable to Edwards Lifesciences Corporation$ 351.9$ 340.5
Earnings per share:  
Basic (in dollars per share)$ 0.58$ 0.56
Diluted (in dollars per share)$ 0.58$ 0.56
Weighted-average number of common shares outstanding:  
Basic (in shares)601.6607.5
Diluted (in shares)604.1610.9

EW Balance Sheet

2024-03-31
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 1,224.6$ 1,144.0
Short-term investments (Note 5)473.0500.5
Accounts receivable, net of allowances of $13.5 and $8.3, respectively817.6775.1
Other receivables59.361.8
Inventories (Note 2)1,207.31,168.2
Prepaid expenses138.1146.8
Other current assets250.6239.3
Total current assets4,170.54,035.7
Long-term investments (Note 5)455.6583.9
Property, plant, and equipment, net1,767.91,749.4
Operating lease right-of-use assets98.494.0
Goodwill1,252.81,253.5
Other intangible assets, net446.8428.4
Deferred income taxes776.7754.6
Other assets (Note 2)767.6463.7
Total assets9,736.39,363.2
Current liabilities  
Accounts payable212.3201.4
Accrued and other liabilities (Note 2)873.7969.1
Operating lease liabilities24.824.9
Total current liabilities1,110.81,195.4
Long-term debt597.2597.0
Taxes payable79.680.6
Operating lease liabilities77.273.0
Uncertain tax positions336.6339.3
Litigation settlement accrual82.094.2
Other liabilities266.5264.3
Total liabilities2,549.92,643.8
Commitments and contingencies (Note 11)
Stockholders' equity  
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding          0.00.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 651.8 and 650.5 shares issued, and 602.4 and 601.1 shares outstanding, respectively651.8650.5
Additional paid-in capital2,379.82,274.4
Retained earnings9,344.38,992.4
Accumulated other comprehensive loss (Note 12)(233.3)(242.8)
Treasury stock, at cost, 49.4 and 49.4 shares, respectively(5,024.7)(5,024.5)
Total Edwards Lifesciences Corporation stockholders' equity7,117.96,650.0
Noncontrolling interest68.569.4
Total stockholders' equity7,186.46,719.4
Total liabilities and equity$ 9,736.3$ 9,363.2
EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
 CEO
 WEBSITEedwards.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES17300

Edwards Lifesciences Corp Frequently Asked Questions


What is the ticker symbol for Edwards Lifesciences Corp? What does EW stand for in stocks?

EW is the stock ticker symbol of Edwards Lifesciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edwards Lifesciences Corp (EW)?

As of Thu Jun 13 2024, market cap of Edwards Lifesciences Corp is 52.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EW stock?

You can check EW's fair value in chart for subscribers.

What is the fair value of EW stock?

You can check EW's fair value in chart for subscribers. The fair value of Edwards Lifesciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Edwards Lifesciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EW so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Edwards Lifesciences Corp a good stock to buy?

The fair value guage provides a quick view whether EW is over valued or under valued. Whether Edwards Lifesciences Corp is cheap or expensive depends on the assumptions which impact Edwards Lifesciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EW.

What is Edwards Lifesciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, EW's PE ratio (Price to Earnings) is 37.38 and Price to Sales (PS) ratio is 8.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EW PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Edwards Lifesciences Corp's stock?

In the past 10 years, Edwards Lifesciences Corp has provided 0.35 (multiply by 100 for percentage) rate of return.